Shingles and the Shingrix Vaccine: Who Should Get It

The short answer#

Two groups should get Shingrix (the recombinant zoster vaccine): every adult 50 and older, and adults 19 and older whose immune system is or will be weakened by disease or treatment. It is given as two shots, usually 2 to 6 months apart. In trials, Shingrix lowered the risk of shingles by about 90 percent in older adults, and that protection has held up for roughly a decade. The common reactions, a sore arm, tiredness, and muscle aches, tend to peak after the second dose and pass within a few days.

Key points#

• Shingrix is the only shingles vaccine available in the United States. The older live vaccine (Zostavax) has not been sold here since November 2020.
• The CDC's Advisory Committee on Immunization Practices (ACIP) recommends 2 doses for all adults 50 and older, and for adults 19 and older who are or will be immunocompromised.
• Standard spacing is 2 to 6 months between doses. A shorter 1 to 2 month gap is an option for people who are immunosuppressed and need protection sooner.
• Efficacy against shingles was about 97 percent in adults 50 and older and about 90 percent in those 70 and older, with roughly 89 to 91 percent protection against postherpetic neuralgia, the lingering nerve pain that is the disease's worst common complication.
• Protection is durable. Pooled efficacy stayed near 88 percent through about 11 years of follow-up.
• Side effects are common but short-lived, a median of 2 to 3 days, and are stronger after the second dose. They reflect the immune system responding, not shingles itself.
• A past episode of shingles, a prior Zostavax dose, and not knowing whether you ever had chickenpox are all reasons to vaccinate, not reasons to skip it.

What is shingles, and what is postherpetic neuralgia?#

Shingles (herpes zoster) is a reactivation of the same virus that causes chickenpox, the varicella-zoster virus. After a childhood case of chickenpox, the virus stays dormant in nerve tissue for decades. When it wakes up, usually as the immune system ages or is suppressed, it travels down a single nerve and produces a painful, blistering rash in a band on one side of the body. About 1 in 3 people in the United States will have shingles at some point, and the risk climbs steeply after age 50.

The rash heals in a few weeks, but the nerve pain can outlast it. When pain persists for 90 days or more after the rash clears, it is called postherpetic neuralgia (PHN). PHN can be severe and stubborn, lasting months, and it becomes both more likely and more lasting with age. Other serious forms, including shingles that involves the eye or spreads widely in someone immunocompromised, are covered separately in our material on complicated herpes zoster. The point that drives the vaccine recommendation is simple: shingles is common, its main complication is hard to treat, and both get worse with age.

Who should get the shingles vaccine?#

The recommendation splits along two lines, age and immune status.

A few practical points clear up most of the questions people ask. You should still get Shingrix if you have already had shingles, because the illness can recur; wait until the acute episode has settled before vaccinating. You should get it even if you received the old Zostavax vaccine years ago. You do not need a blood test or proof that you had chickenpox: nearly all US adults born before 1980 were infected in childhood, so vaccination proceeds without checking. The immunocompromised group includes a wide range: recipients of a stem cell or solid organ transplant, people with blood cancers or solid tumors on treatment, people living with HIV, those with primary immunodeficiencies, and people taking immunosuppressive drugs for autoimmune conditions. Because Shingrix is a recombinant, non-live vaccine (a piece of a viral protein plus an adjuvant rather than a weakened virus), it can be given safely to these patients, which the older live vaccine could not.

How effective is Shingrix?#

Very. Two large randomized trials, ZOE-50 and ZOE-70, measured how well the vaccine prevented shingles compared with placebo.

To put the relative numbers in absolute terms: shingles is common enough that a roughly 90 percent reduction removes most of the lifetime risk for a vaccinated older adult, and it prevents most cases of the nerve pain that is the reason to fear the disease. Protection does not vanish after a few years. In the long-term follow-up, pooled efficacy against shingles stayed near 88 percent across the full period, and yearly estimates remained high through about 11 years after the first dose. A booster is not currently recommended for people who completed the two-dose series.

Protection is somewhat lower, but still worthwhile, in people who are immunocompromised, and it varies by condition. In the trials that supported the immunocompromised recommendation, efficacy against shingles ranged from about 68 percent in autologous stem cell transplant recipients to roughly 87 percent in people with blood cancers and about 90 percent in those with immune-mediated diseases. For patients at high risk of severe, prolonged, or disseminated shingles, even the lower figure represents meaningful protection.

What are the side effects of Shingrix?#

Shingrix is reactogenic, meaning it commonly produces a noticeable but temporary reaction. Among adults 50 and older in the trials, counting both doses, the frequencies were roughly:

• Sore arm at the injection site: about 78 percent, with redness (about 38 percent) and swelling (about 26 percent) less common.
• Whole-body reactions: muscle aches and fatigue about 45 percent each, headache about 38 percent, shivering about 27 percent, fever about 21 percent, and stomach upset about 17 percent.

These reactions had a median duration of 2 to 3 days. About 1 in 6 people had a reaction strong enough to briefly interfere with normal activities, and such reactions were somewhat more frequent after the second dose than the first. That pattern is worth knowing in advance so a strong response to dose two is not mistaken for something wrong; it is the expected sign of the immune system building protection. Older adults, those 70 and up, tended to report fewer reactions than people in their fifties and sixties. Shingrix cannot give you shingles or chickenpox, because it contains no live virus.

Serious reactions are rare. Guillain-Barre syndrome (GBS), a temporary but serious nerve disorder, has been observed at a slightly increased rate in postmarketing surveillance during the 42 days after vaccination, on the order of a few extra cases per million doses in adults 65 and older. For context, shingles itself also raises the short-term risk of GBS, so the comparison is not vaccine versus zero risk. As with any injected vaccine, fainting can occur shortly after the shot, and a severe allergic reaction is possible but uncommon.

Who should wait, and who should not get it?#

The main reason not to receive Shingrix is a history of a severe allergic reaction (such as anaphylaxis) to a previous dose or to any component of the vaccine. Beyond that, timing matters more than eligibility for most people. Postpone the vaccine if you are in the middle of an active shingles episode; wait until the acute illness has passed. Reasonable practice is also to defer routine vaccination during a moderate or severe acute illness with fever, then catch up once you have recovered. Data in pregnancy are limited, so vaccination is generally deferred until after pregnancy unless there is a specific reason to proceed; this is a conversation to have with your clinician. Feeling run down for a day or two after a prior dose is not a contraindication to completing the series.

How does Shingrix fit the adult immunization schedule?#

On the CDC adult schedule, Shingrix appears as a routine recommendation for everyone 50 and older, and as a risk-based recommendation for immunocompromised adults 19 and older. If you have trouble reading that grid, our guide on how to read the adult immunization schedule without getting lost walks through the color coding, and the overview of the vaccines that matter more with age puts shingles alongside the other shots that earn their place as the years add up. Shingrix can generally be given at the same visit as other adult vaccines, such as the influenza and pneumococcal vaccines, using separate injection sites. For people who are about to start immunosuppressive therapy, completing the series beforehand often produces a better response, so timing is worth planning with the prescribing team. All of this sits within the broader habits of prevention, nutrition, and travel health that keep routine care from slipping.

When to seek care#

Most reactions need nothing but time. Seek prompt medical attention if you notice:

• Signs of a severe allergic reaction soon after the shot: hives, swelling of the face or throat, wheezing, a fast heartbeat, or dizziness. Call emergency services.
• Symptoms that could suggest GBS within about six weeks of vaccination: new weakness or tingling, especially if it spreads or affects walking, breathing, or swallowing.
• A shingles rash near or around an eye, a widely spreading rash, or severe pain, particularly if you are immunocompromised. These need urgent evaluation.
• A rash that becomes increasingly red, warm, swollen, or pus-filled, which can signal a bacterial skin infection.

Whether and when to receive Shingrix is a decision to make with a clinician who knows your health history.